News - GlaxoSmithKline, Europe

Filter

Current filters:

GlaxoSmithKlineEurope

Popular Filters

GSK receives EU approval for Mekinist for melanoma

GSK receives EU approval for Mekinist for melanoma

04-07-2014

The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline’s Mekinist…

EuropeGlaxoSmithKlineMekinistOncologyPharmaceuticalRegulation

EU approval for GSK and Genmab’s Arzerra as first-line CLL therapy

EU approval for GSK and Genmab’s Arzerra as first-line CLL therapy

03-07-2014

The European Commission has granted marketing authorization for a new indication for the use of UK pharma…

ArzerraEuropeGenmabGlaxoSmithKlineOncologyPharmaceuticalRegulation

EU5 payers looking to superior clinical efficacy for COPD

EU5 payers looking to superior clinical efficacy for COPD

30-06-2014

Surveyed pulmonologists in the European Union (EU5; France, Germany, Italy, Spain and the UK) estimate…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16-06-2014

UK pharma major GlaxoSmithKline announced the results from the Phase III PETIT2 study evaluating the…

eltrombopagEuropeGlaxoSmithKlineHealth Medical PharmaHematologyItalyMajorMedicinePharmaceuticalResearchThrombocytopenic purpura

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

09-05-2014

The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline and partner…

Anoro ElliptaEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

GSK gains EU marketing OK for Incruse for COPD; initiates tafenoquine Ph III program

GSK gains EU marketing OK for Incruse for COPD; initiates tafenoquine Ph III program

29-04-2014

UK pharma giant GlaxoSmithKline has received marketing authorization from the European Commission for…

EuropeGlaxoSmithKlineIncrusePharmaceuticalRespiratory and PulmonarytafenoquineTropical diseases

Positive CHMP opinion for GSK’s Mekinist in metastatic melanoma

27-04-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

EuropeGlaxoSmithKlineMekinistOncologyPharmaceuticalRegulation

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

GSK announces delay in Mekinist/Tafinlar MAA; EU approval of Eperzan

27-03-2014

UK pharma giant GlaxoSmithKline released a couple of news items yesterday, one slightly negative regarding…

DiabetesEperzanEuropeGlaxoSmithKlineMekinistOncologyPharmaceuticalRegulationTafinlar

Novel collaboration to use genomics and big data to drive drug discovery

27-03-2014

A pioneering public-private research initiative between UK pharma giant GlaxoSmithKline, the European…

BiotechnologyEuropeGlaxoSmithKlineResearch

Cost is preventing boys receiving anti-cancer vaccine for HPV

Cost is preventing boys receiving anti-cancer vaccine for HPV

13-02-2014

While national health systems have been pushing to increase the human papillomavirus (HPV) vaccine uptake…

CervarixEuropeGardasilGlaxoSmithKlineHealthcareMerck & CoPharmaceuticalUSAVaccines

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

Back to top